Rohit Talwani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rohit Talwani has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Akira A. Shishido
Division of Infectious Disease, Department of Medicine, Westchester Medical Center at New York Medical College, Valhalla; and
1 shared publication Alexander Engelmann
Department of Ophthalmology and Visual Sciences, University of Maryland, Baltimore, Maryland
1 shared publication- Boris Julg
Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, 600 Main street, 02139, Cambridge, MA, USA.
1 shared publication - Eleanor Wilson
Moderna, Inc. , Cambridge, Massachusetts
1 shared publication - Emily Comstock
Maple Hill Veterinary Service, Danville, VT, USA
1 shared publication - Harpreet Kaur
Division of Infectious Diseases, University of Maryland Medical Center, Baltimore, Maryland
1 shared publication
Latest Publications
- Open Access
- 1 May 2022
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 1 (3)
A Case of Steroid-Responsive Multisystem Inflammatory Syndrome in Adults With SARS-CoV-2
While the COVID-19 pandemic continues to evolve, different phenotypic variants of the disease are being recognized. Multisystem inflammatory syndrome in adults is an emerging entity that has yet to...
- 1 May 2022
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 1 (3)
Open AccessA Case of Steroid-Responsive Multisystem Inflammatory Syndrome in Adults With SARS-CoV-2
While the COVID-19 pandemic continues to evolve, different phenotypic variants of the disease are being recognized. Multisystem inflammatory syndrome in adults is an emerging entity that has yet to...
- Open Access
- 4 December 2021
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (Supplement) , S515-S516
851. Rate of Sexually Transmitted Infections and Engagement in HIV Pre-Exposure Prophylaxis at the Veterans Affair Maryland Health System
Rates of sexually transmitted infections (STIs) and uptake of HIV pre-exposure prophylaxis (PrEP) during the 2020 coronavirus pandemic are unknown. We evaluated data from the Veterans Affair Maryland Health Care System (VAMHCS) data to determine rates of STI and PrEP linkage in our Veterans. We extracted patient-level data on demographics, STI testing (chlamydia, gonorrhea, and syphilis), International Classification of Diseases (ICD) diagnosis codes and refills of TDF-FTC and TAF-FTC. We compared the ratio of positive STI tests in 2018, 2019 and 2020 using chi-square tests. Individuals eligible for PrEP were defined as patients with a newly positive STI result or an ICD diagnosis of: high risk sexual behavior; an STI mentioned above; or gender identity disorder. We excluded anyone with a positive HIV test or a creatinine >1.8. We identified patients initiated on PrEP through pharmacy refill data to define initiation of care. Finally, we used chi-square tests to compare differences of initiation of PrEP between years and demographics. The STI positivity rate significantly increased (p< 0.01) from 44.2% (2018) and 42.9% (2019) to 61.6% (2020) [Table 1]. The median ages of those who had a positive STI test were 50 (2018), 44 (2019) and 44 (2020). In 2020, 17% of patients eligible for PrEP filled PrEP. Engagement was similar (p=0.33) in 2019 and 2018, where 14% and 11.6% of patients eligible for PrEP received a prescription (p-value=0.33) [Figure 1]. The median age of those refilling PrEP were: 44 (2018); 43 (2019) and 41 (2020)). In 2020, we observed a statistically significant difference (p< 0.01) in initiation of PrEP in care among Black patients with 11.7% of eligible patients filling PrEP as compared to white patients (26.2%) and other races (23.3%) [Figure 2]. Table 1. Rate of positive tests at VAMHCS from 2018-2020. Figure 1. PrEP Cascade at VAMHCS by year. Non-statistically significant (P=0.33) when comparing engagement in care between different years. Figure 2. Racial distribution of PrEP eligibility and initiation by year at the VAMHCS. While during the coronavirus pandemic in 2020, fewer Veterans sought STI testing at the VAMHCS, the number of positive STI results remained steady, leading to a higher positivity rate. The rate of initiation of PrEP did not differ between 2020, 2019 and 2018. Racial inequities in initiation of PrEP increased in 2020. All Authors: No reported disclosures
- 4 December 2021
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (Supplement) , S515-S516
Open Access851. Rate of Sexually Transmitted Infections and Engagement in HIV Pre-Exposure Prophylaxis at the Veterans Affair Maryland Health System
Rates of sexually transmitted infections (STIs) and uptake of HIV pre-exposure prophylaxis (PrEP) during the 2020 coronavirus pandemic are unknown. We evaluated data from the Veterans Affair Maryland Health Care System (VAMHCS) data to determine rates of STI and PrEP linkage in our Veterans. We extracted patient-level data on demographics, STI testing (chlamydia, gonorrhea, and syphilis), International Classification of Diseases (ICD) diagnosis codes and refills of TDF-FTC and TAF-FTC. We compared the ratio of positive STI tests in 2018, 2019 and 2020 using chi-square tests. Individuals eligible for PrEP were defined as patients with a newly positive STI result or an ICD diagnosis of: high risk sexual behavior; an STI mentioned above; or gender identity disorder. We excluded anyone with a positive HIV test or a creatinine >1.8. We identified patients initiated on PrEP through pharmacy refill data to define initiation of care. Finally, we used chi-square tests to compare differences of initiation of PrEP between years and demographics. The STI positivity rate significantly increased (p< 0.01) from 44.2% (2018) and 42.9% (2019) to 61.6% (2020) [Table 1]. The median ages of those who had a positive STI test were 50 (2018), 44 (2019) and 44 (2020). In 2020, 17% of patients eligible for PrEP filled PrEP. Engagement was similar (p=0.33) in 2019 and 2018, where 14% and 11.6% of patients eligible for PrEP received a prescription (p-value=0.33) [Figure 1]. The median age of those refilling PrEP were: 44 (2018); 43 (2019) and 41 (2020)). In 2020, we observed a statistically significant difference (p< 0.01) in initiation of PrEP in care among Black patients with 11.7% of eligible patients filling PrEP as compared to white patients (26.2%) and other races (23.3%) [Figure 2]. Table 1. Rate of positive tests at VAMHCS from 2018-2020. Figure 1. PrEP Cascade at VAMHCS by year. Non-statistically significant (P=0.33) when comparing engagement in care between different years. Figure 2. Racial distribution of PrEP eligibility and initiation by year at the VAMHCS. While during the coronavirus pandemic in 2020, fewer Veterans sought STI testing at the VAMHCS, the number of positive STI results remained steady, leading to a higher positivity rate. The rate of initiation of PrEP did not differ between 2020, 2019 and 2018. Racial inequities in initiation of PrEP increased in 2020. All Authors: No reported disclosures
- 1 June 2021
- Published by Oxford University Press (OUP)
- p. 199-217
The HIV Reservoir and Cure and Remission Strategies
This chapter covers the HIV reservoir and cure and remission strategies. It details the importance of why we should try to cure HIV and includes clinical observations where the concept of a “functional cure” has been introduced. Early establishment and persistence of the latent HIV-1 reservoir are discussed as well as latency reversal approaches and latency silencing. A variety of immune-enhancing and/or immune-modulating strategies and immunomodulatory treatments are reviewed. Special attention is paid to therapeutic and preventive vaccines.
- 1 June 2021
- Published by Oxford University Press (OUP)
- p. 199-217
The HIV Reservoir and Cure and Remission Strategies
This chapter covers the HIV reservoir and cure and remission strategies. It details the importance of why we should try to cure HIV and includes clinical observations where the concept of a “functional cure” has been introduced. Early establishment and persistence of the latent HIV-1 reservoir are discussed as well as latency reversal approaches and latency silencing. A variety of immune-enhancing and/or immune-modulating strategies and immunomodulatory treatments are reviewed. Special attention is paid to therapeutic and preventive vaccines.